

## DEPARTMENT OF HEALTH AND HUMAN SERVICES



Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.

## **Silver State Scripts Board Meeting Minutes**

**Date of Meeting**: Thursday, September 28, 2023, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agen	da Item	Record			Notes
1. (	Closed Executive Session				•
а	. Call to Order and Roll Call	Chairperson Mark Decerbo called the me	eting to order at	t 1:01 p.m. on	DHCFP Staff Present were as
		September 28, 2023.			follows:
		Chairperson Decerbo took the roll.	Present	Absent	<ul> <li>Lither, Gabriel, Senior</li> <li>Deputy Attorney General</li> <li>(SDAG)</li> </ul>
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm. D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> </ul>			<ul> <li>Clemons, Roshanda, MD, Medicaid Medical Director</li> <li>Olsen, David, Social Services Chief III</li> <li>Flowers, Ellen, Program Officer I (PO)</li> </ul>
		<ul><li>Isabella Niezborala, Pharm.D.</li><li>Leana Ramirez, Pharm.D.</li></ul>			Nevada Medication
		Aditi Singh, MD			Assistance Program (NMAP) Staff Present were as follows:  Johnson, Tory, Health Program Manager II

		<ul> <li>Cowan, Sarah, Health Program Specialist I</li> <li>Magellan Rx Staff Present were as follows:</li> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>Perez, Melissa, Sr. Business Analyst</li> </ul>
b. Financial Review of Drug Classes with Proposed Changes	Chairman Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review.  Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.  Dr. Mishra presented the Financial Review of the - Established Drug Classes Being Reviewed Due to the Release of New Drugs.  • Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations  • Growth Hormone Modifiers  • Targeted Immunomodulators  • Atypical Antipsychotics Long Acting Injectables  Dr. Mishra presented the Financial Review of the Established Drug Classes Being Reviewed Due to the Release of New Generics.  • Ophthalmic Corticosteroids  • Dipeptidyl Peptidase-4 Inhibitors (DPP-4) and Combinations with Metformin	

	Dr. Mishra presented the Financial Review	of the New D	rug Classes for	
	Proposed Addition.			
	<ul> <li>Immune Globulins</li> </ul>			
	Dr. Mishra presented the Financial Review	v of the Establi	shed Drug	
	Classes with Proposed Changes.			
	<ul> <li>Movement Disorders</li> </ul>			
	<ul> <li>Topical Retinoids</li> </ul>			
	<ul> <li>Opioid Agonists</li> </ul>			
	<ul> <li>Mixed Acting Opioid Analgesics</li> </ul>			
	<ul> <li>Leukotriene Receptor Antagonists</li> </ul>	5		
	<ul> <li>Vasodilators – Oral</li> </ul>			
	<ul> <li>Vasodilators – Inhaled</li> </ul>			
	Monoclonal Antibodies for Respire	atory Condition	ns	
2. Open Public Meeting				•
a. Call to Order and Roll Call	Chairman Decerbo called the meeting to o	order at 2:07 p	.m. on	DHCFP Staff Present were as
	September 28, 2023.			follows:
				<ul> <li>Lither, Gabriel, Senior</li> </ul>
	A quorum was present.			Deputy Attorney General
				(SDAG)
	Chairman Decerbo took the roll.			<ul> <li>Clemons, Roshanda, MD,</li> </ul>
				Medicaid Medical
		Present	Absent	Director
				<ul> <li>Olsen, David, Social</li> </ul>
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$		Services Chief III
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$		<ul> <li>Flowers, Ellen, Program</li> </ul>
	<ul> <li>Joseph Adashek, MD</li> </ul>		$\boxtimes$	Officer I (PO)
	Mark Crumby, Pharm. D.	$\boxtimes$		
	Elizabeth Gonzalez, Pharm.D.		$\boxtimes$	Nevada Medication
	Sapandeep Khurana, MD	$\boxtimes$		Assistance Program (NMAP)
	<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>		$\boxtimes$	Staff Present were as
	Leana Ramirez, Pharm.D.	$\boxtimes$		follows:
	Aditi Singh, MD	$\boxtimes$		Johnson, Tory, Health
				Program Manager II

			<ul> <li>Cowan, Sarah, Health Program Specialist I</li> <li>Magellan Rx Staff Present were as follows:</li> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>Perez, Melissa, Sr. Business Analyst</li> </ul>
b.	Approval for previous Meeting Minutes from June 22, 2023	By unanimous consent, the minutes were approved as revised.	
C.	Public Comments	Telephonic and web comment was called for, and the phone lines were opened.	
		Public comment was provided by Leah Case on behalf of Nevada Psychiatric Association.	
d.	Status Update by DHCFP	<ul> <li>Chief of Pharmacy Services, David Olsen, provided announcements.</li> <li>Organizational change: The unit is now being led by Doctor Roshanda Clemons, who is the Medical Director for the Division. Also, the durable medical equipment (DME) program is now part of the unit.</li> <li>In August a public hearing was held as a step to update the reimbursement methodology for physician administrated drugs (PAD) through state plan amendment. Centers for Medicare &amp; Medicaid Services (CMS) approved the amendment earlier this month. It will be effective December 1, 2023, which will in the beginning of the Medicare Part D fee schedule being incorporated into the PAD reimbursement methodology. Please note this work is</li> </ul>	

	<ul> <li>an addition to the PAD management project, which was implemented July 1, 2023 and introduced the first fee schedule.</li> <li>Up next the division is also working on a project in support of Senate Bill 156. This bill expands the scope of billable services and prescribing for Nevada Medicaid Provider Type 91, which is a licensed pharmacist. After implementation next year, pharmacists enrolled with Nevada Medicaid will be able to prescribe medication assisted treatment for opioid use disorder.</li> <li>In addition, we are working on a number of other bills. <i>In</i> regard to Senate Bill 167 the Division did an analysis during last session and determined there would be a \$0.00 fiscal note. Step therapy is under the Drug Use Review Board, which meet next on October 19, 2023, but currently we do not have step therapy protocols as part of the</li> </ul>	
	criteria for the drugs specific to SB 167.	
3. Clinical Presentations		
A. For Possible Action: Discussion and possible adoption of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations		
i. <u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was provided.	
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Inpefa, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.  Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and action by Board to	Chairman Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Board Member	

approve clinical/therapeutic	Sapandeep Khurana seconded the motion.					
equivalency of agents in	A vote was taken, and the results were as	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
class.						
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
	<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>	$\boxtimes$				
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
	<ul> <li>Mark Crumby, Pharm.D</li> </ul>	$\boxtimes$				
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$				
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$		
	Leana Ramirez, Pharm.D	$\boxtimes$				
	Aditi Singh, MD	$\boxtimes$				
iv. Presentation of recommendations for PDL	Dr. Mishra recommended adding Inpefa	on the PDL	as non	-preferred.		
inclusion by MagellanRx						
v. Discussion by Board and	Vice-Chair Kate Ward moved to approve			-		
action by Board for approval of drugs for	presented by Magellan and Board Memb	er Khurana	secon	ded the		
inclusion on the PDL.						
	A vote was taken, and the results were as	follows fro	om mei	mbers in		
	attendance (in favor, against, and absten	tions wher	e appli	cable):		
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
	Kate Ward, Pharm.D., Vice-Chair					
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
	Mark Crumby, Pharm.D	$\boxtimes$				
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$		

	<ul> <li>Sapandeep Khurana, MD</li> </ul>		
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>		
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>		
	<ul> <li>Aditi Singh, MD</li> </ul>		
<b>B.</b> For Possible Action: Discussion and possible adoption of Growth Hormone Modifiers			
i. <u>Public comment</u>	Telephonic and web comment was called opened.	for, and the phone lines were	
	Public comment was provided by Paul Mi Economics and Outcomes Research on be		
ii. Drug class review presentation by MagellanRx	Dr. Mishra discussed Ngenla, Sogroya and within this drug class. He presented the a and noted the indication, mechanism of a Dr. Mishra recommended the Board constherapeutically equivalent.	vailability within the drug class action, and efficacy studies.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the continuous therapeutically equivalent presented by Markhurana seconded the motion.  A vote was taken, and the results were as attendance (in favor, against, and abstentions)	Magellan and Board Member follows from members in	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> </ul>	Yes No Abst.  \times \cap \cap \cap \cap \cap \cap \cap \cap	
	<ul> <li>Mark Crumby, Pharm,D</li> </ul>	$\bowtie$ $\square$ $\square$	

		<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$	
		Sapandeep Khurana, MD	$\boxtimes$			
		<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
		<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
		Aditi Singh, MD	$\boxtimes$			
iv.		Dr. Mishra recommended adding Ngenla	, Sogroya a	nd Zon	nacton on the	
	recommendations for	PDL as non-preferred.				
	PDL inclusion by					
	MagellanRx					
	Discussion by Decad and	Vice Chain Monday and a constant the sa				
V.	Discussion by Board and action by Board for	Vice-Chair Ward moved to approve the p	•	_	•	
	approval of drugs for	by Magellan and Board Member Leana R	annez seco	Jilueu	ine motion.	
	inclusion on the PDL.	A vote was taken, and the results were a	follows fro	nm mer	nhers in	
	merasion on the ribe.	attendance (in favor, against, and abster				
		(		-	,	
			Yes	No	Abst.	
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$			
		<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>	$\boxtimes$			
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
		<ul> <li>Mark Crumby, Pharm.D</li> </ul>	$\boxtimes$			
		<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$	
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
		<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
		<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
		Aditi Singh, MD	$\boxtimes$			
					105	
vi.	Board Member	Dr. Khurana provided a comment asking	if there is a	ny real	-lite	
	Comment	perspective.				

<b>C.</b> For Possible Action: Discussion					ı	
and possible adoption of					ı	
Targeted Immunomodulators					ı	
i. <u>Public Comment</u>	Telephonic and web comment was called opened.	for, and th	e phor	ne lines were		
	Public comment was provided by Ann Lyo Scientific Affairs.	ons, Pharm	acist w	ith Amgen	l	
ii. Drug class review	Dr. Mishra discussed adalimumab-adaz, a		• • •	•		
presentation by MagellanRx	Hadlima, Hulio, Hyrimoz, Idacio, Spevigo, the new products within this drug class. I	•	•	• •	ı	
Magenanity	within the drug class and noted the indica	•		•	ı	
	efficacy studies.	ŕ		•	ı	
					ı	
	Dr. Mishra recommended the Board const therapeutically equivalent.	ider the cla	ass clin	ically and	ı	
	therapeuticany equivalent.				ı	
iii. Discussion by Board	Chairman Decerbo moved to accept the c					
and action by Board to	therapeutically equivalent presented by I seconded the motion.	Magellan aı	nd Vice	-Chair Ward	ı	
approve clinical/therapeutic	seconded the motion.				ı	
equivalency of agents in	A vote was taken, and the results were as	follows fro	m mer	nbers in	ı	
class.	attendance (in favor, against, and absten	tions where	e appli	cable):	ı	
		Yes	No	Abst.	ı	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			ı	
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			ı	
	Joseph Adashek, MD			$\boxtimes$	ı	
	Mark Crumby, Pharm.D	$\boxtimes$			ı	
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	ı	
	Sapandeep Khurana, MD				ı	
	Isabella Niezborala, Pharm.D			$\bowtie$	i	

	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
	Aditi Singh, MD	$\boxtimes$			
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding adalimumab-adaz, adalimumab-fkjp, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Spevigo, Uplizna, Yuflyma, and Yusimry on the PDL as non-preferred.				
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice-Chair Ward moved to approve the proposed changes as presented by Magellan and Board Member Mark Crumby seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	Joseph Adashek, MD			$\boxtimes$	
	Mark Crumby, Pharm.D	$\boxtimes$			
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D			$\boxtimes$	
	Leana Ramirez, Pharm.D	$\boxtimes$			
	Aditi Singh, MD	$\boxtimes$			
<b>D.</b> For Possible Action: Discussion	1				
and possible adoption of					
Atypical Antipsychotics Long					
Acting Injectables					
i. <u>Public Comment</u>	Telephonic and web comment was called opened.	d for, and th	ne pho	ne lines were	e

	Public comment was provided by Robin F of the State Chapter of the National Allia	•			
	Public comment was provided by Kenneth Berry, Pharmacist and Medical Science Director with Alchemies.				
	Public comment was provided by Mande Medical Affairs.	ep Sohal, P	harma	cist with Teva	
<ul><li>ii. Drug class review presentation by MagellanRx</li></ul>	Dr. Mishra discussed Abilify Asimtufil and Uzedy, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.				
	Dr. Mishra recommended the Board constherapeutically equivalent.	sider the cla	ass clin	ically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Chairman Decerbo moved to accept the continuous therapeutically equivalent presented by Khurana seconded the motion.		•		
equivalency of agents in class.	A vote was taken, and the results were as attendance (in favor, against, and absten				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	Mark Crumby, Pharm.D	$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
	Sapandeep Khurana, MD	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			1

	Aditi Singh, MD					
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Abilify as preferred.	y Asimtufil aı	nd Uze	dy on the P	PDL	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to approve the proposed changes as presented by Magellan and Board Member Khurana seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair					
	Kate Ward, Pharm.D., Vice-Chair					
	Joseph Adashek, MD			$\boxtimes$		
	Mark Crumby, Pharm.D					
	Elizabeth Gonzalez, Pharm.D.					
	Sapandeep Khurana, MD					
	Isabella Niezborala, Pharm.D			$\boxtimes$		
	Leana Ramirez, Pharm.D					
	Aditi Singh, MD	$\boxtimes$				
E. For Possible Action: Discussion and possible adoption of Ophthalmic Corticosteroids						
i. <u>Public Comment</u>	Telephonic and web comment was calle opened.	ed for, and th	ne phoi	ne lines we	re	
	No public comment was provided.					

ii.	Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board cons therapeutically equivalent.	der the class clinically and
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the of therapeutically equivalent presented by I Ramirez seconded the motion.  A vote was taken, and the results were as attendance (in favor, against, and absten	Magellan and Board Member follows from members in
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>	Yes No Abst.  □
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding generic preferred and moving brand Durezol to n	·
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to approve the presented by Magellan and Vice-Chair W  A vote was taken, and the results were as attendance (in favor, against, and absten	follows from members in

	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>				
F. For Possible Action: Discussion and possible adoption of Dipeptidyl Peptidase-4 Inhibitors (DPP-4) and Combinations with Metformin					
i. <u>Public Comment</u>	Telephonic and web comment was called opened.  Public comment was provided by Ben Dro Medical Affairs.  Public comment was provided by Brandor for Sanofi.	ese, Pharmac	cist with	Amgen	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consi therapeutically equivalent.	der the class	clinically	and and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Chairman Decerbo moved to accept the of the rapeutically equivalent presented by seconded the motion.  A vote was taken, and the results were as	Magellan and	d Vice-Ch		

	equivalency of agents in	attendance (in favor, against, and abster	itions wher	e appli	cable):		
	class.						
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair					
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
		Joseph Adashek, MD					
		Mark Crumby, Pharm.D	$\boxtimes$				
		Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
		Sapandeep Khurana, MD	$\boxtimes$				
		Isabella Niezborala, Pharm.D			$\boxtimes$		
		Leana Ramirez, Pharm.D	$\boxtimes$				
		Aditi Singh, MD	$\boxtimes$				
iv.	Presentation of	Dr. Mishra recommended adding Jentad			•		
	recommendations for PDL	and moving Kazano and Nesina from nor	•				
	inclusion by MagellanRx	adding saxagliptin and saxagliptin/metfo preferred. Will be removing Kombiglyze					
		been discontinue by the manufacturer.	AN allu Olig	siyza as	product nave		
		been discontinue by the mandideturer.					
V.	Discussion by Board and	Vice-Chair Ward moved to approve the p	roposed ch	anges	as presented		
	action by Board for	by Magellan and Board Member Khurana	a seconded	the mo	otion.		
	approval of drugs for						
	inclusion on the PDL.	A vote was taken, and the results were as	s follows fro	om me	mbers in		
		attendance (in favor, against, and abster	itions wher	e appli	cable):		
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair					
		Kate Ward, Pharm.D., Vice-Chair					
		Joseph Adashek, MD					
		Mark Crumby, Pharm.D					
		Elizabeth Gonzalez, Pharm.D.					
		<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$				

	Isabella Niezborala, Pharm.D			$\boxtimes$		
	Leana Ramirez, Pharm.D	$\boxtimes$				
	Aditi Singh, MD	$\boxtimes$				
<b>G.</b> For Possible Action: Discussion and possible adoption of Immune Globulins.						
i. <u>Public Comment</u>	Telephonic and web comment was called opened.  No public comment was provided.	d for, and th	e phor	ne lines were		
ii. Drug class review	Dr. Mishra recommended the Board cons	ider the cla	cc clini	cally and	+	
presentation by	therapeutically equivalent.	sider the cia	33 CIIIII	cally allu		
MagellanRx	therapeatically equivalent.					
S .						
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in	Chairman Decerbo moved to accept the therapeutically equivalent presented by seconded the motion.  A vote was taken, and the results were a	Magellan aı	nd Vice	Chair Ward		
class.	attendance (in favor, against, and abster	itions where	e applio	cable):		
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
	Mark Crumby, Pharm.D	$\boxtimes$				
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
	Sapandeep Khurana, MD	$\boxtimes$				
	Isabella Niezborala, Pharm.D			$\boxtimes$		
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$				

	Aditi Singh, MD				
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Immurwith Gamunex-C, Gammagard Liquid, Hias preferred and Asceniv, Bivigam, Cutar Flebogamma, Gamastan, Gamastan S-D, Gammaplex, Hepagam B, Hyperhep B S-Octagam, Panzyga, Varizig and Xembify	zentra and F quig, Cuvitru Gammagan D, Hyperrab	Priviger I, Cytog d S-D, ( , Hyqvi	n on the PD gam, Gammaked	DL d,
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to accept to a Vice-Chair Ward seconded the motion.  A vote was taken, and the results were a attendance (in favor, against, and abster	s follows fro	om mer	nbers in	ind
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	Joseph Adashek, MD			$\boxtimes$	
	Mark Crumby, Pharm.D	$\boxtimes$			
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
	Sapandeep Khurana, MD	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	Leana Ramirez, Pharm.D	$\boxtimes$			
	Aditi Singh, MD				
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice-Chair Ward moved to approve the plant by Magellan and Board Member Ramire  A vote was taken, and the results were a attendance (in favor, against, and abster	z seconded s follows fro	the mo om mer	tion. mbers in	ted
		Yes	No	Abst.	

	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> </ul>				
	<ul> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>				
H. For Possible Action: Discussion and possible adoption of Movement Disorders.					
i. <u>Public Comment</u>	Telephonic and web comment was called opened.  Public comment was provided by Mande Medical Affairs.				
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board con therapeutically equivalent.	sider the cla	ss clini	cally and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the of therapeutically equivalent presented by Ramirez seconded the motion.  A vote was taken, and the results were as attendance (in favor, against, and abster	Magellan ar s follows fro	nd Boar m mem	d Member	
	Mark Decerbo, Pharm.D., Chair	Yes ⊠	No	Abst. □	

	<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>		
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Austed and leaving Austedo XR titration pack as	•	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice-Chair Ward moved to approve prop Magellan and Board Member Khurana se A vote was taken, and the results were a attendance (in favor, against, and abster	econded the motion.	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>	Yes No Abst.	

<ul> <li>For Possible Action: Discussion and possible adoption of Topical Retinoids.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was calle opened.  No public comment was provided.	d for, and th	e phor	ne lines were	
	No public comment was provided.				
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board cor therapeutically equivalent.	nsider the cla	ass clin	ically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the therapeutically equivalent presented by Khurana seconded the motion.  A vote was taken, and the results were a attendance (in favor, against, and abste	Magellan ar	nd Boa om mer	rd Member mbers in	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	Mark Crumby, Pharm.D	$\boxtimes$			
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
	Sapandeep Khurana, MD	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
	Aditi Singh, MD	$\boxtimes$			

<ul> <li>iv. Presentation of recommendations for PDL inclusion by MagellanRx</li> <li>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</li> </ul>	Dr. Mishra recommended moving adapa Epiduo and Tazorac will be removed from longer participate in the Medicaid Drug F  Chairman Decerbo moved to proposed ch Magellan and Vice-Chair Ward seconded  A vote was taken, and the results were as	n PDL as manufacturers no Rebate Program. nanges as presented by the motion.	
metasion on the 1 be.	attendance (in favor, against, and abster		
	account (m. 1816), against, and account	пополительной принадаге,	
		Yes No Abst.	
	Mark Decerbo, Pharm.D., Chair	oxtimes $oxtimes$	
	Kate Ward, Pharm.D., Vice-Chair	oxtimes $oxtimes$	
	<ul> <li>Joseph Adashek, MD</li> </ul>		
	Mark Crumby, Pharm.D		
	Elizabeth Gonzalez, Pharm.D.		
	Sapandeep Khurana, MD		
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>		
	Leana Ramirez, Pharm.D		
	Aditi Singh, MD		
J. For Possible Action:			
Discussion and possible			
adoption of Opioid			
Agonists.	Talambania and wale annuant was as list	I fan and the above lines were	
i. <u>Public Comment</u>	Telephonic and web comment was called opened.	i for, and the phone lines were	
	No public comment was provided.		
<li>ii. New Drug class review presentation by MagellanRx</li>	Dr. Mishra recommended the Board con therapeutically equivalent.	sider the class clinically and	

iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the therapeutically equivalent presented by Khurana seconded the motion.  A vote was taken, and the results were as attendance (in favor, against, and abster	Magellan a	nd Boa om me	rd Member		
		Mark Decerbo, Pharm.D., Chair	Yes ⊠	No	Abst.		
		Kate Ward, Pharm.D., Vice-Chair					
		Joseph Adashek, MD					
		Mark Crumby, Pharm.D					
		Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
		Sapandeep Khurana, MD					
		Isabella Niezborala, Pharm.D			$\boxtimes$		
		Leana Ramirez, Pharm.D	$\boxtimes$				
		Aditi Singh, MD	$\boxtimes$				
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended removing Nucleon placement in alternative class. Also recommended placement in alternative class and alternative class. Also recommended removing Nucleon Class and alternative	mmended r Idian, Opan	emovi a ER aı	ng Avinza, nd Xartemis		
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice-Chair Ward moved to approve the pand Chairman Decerbo seconded the mode.  A vote was taken, and the results were as	tion. s follows fro	om mei	mbers in		
		attendance (in favor, against, and abster	itions wher	e appii	cable):		
		Marile Describes Division D. Chair	Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair     Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice-Chair     Adaphal, MD.					
		Joseph Adashek, MD			$\boxtimes$		

	<ul> <li>Mark Crumby, Pharm.D</li> </ul>	$\boxtimes$			
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$	
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
	Aditi Singh, MD	$\boxtimes$			
K. For Possible Action: Discussion					
and possible adoption of					
Mixed Acting Opioid					
Analgesics.					
<b>G</b>					
i. <u>Public Comment</u>	Telephonic and web comment was cal	led for, and th	e phor	ne lines were	
	opened.				
	No public comment was provided.				
ii. Drug class review	Dr. Mishra recommended the Board co	ancidar tha ala	acc clin	ically and	
ii. Drug class review presentation by	therapeutically equivalent.	Jisidel tile cia	355 CIIII	ically allu	
MagellanRx	therapeuticany equivalent.				
iii. Discussion by Board and	Chairman Decerbo moved to accept th	e class as clin	ically a	nd	
action by Board to	therapeutically equivalent presented by		-		
approve	Khurana seconded the motion.				
clinical/therapeutic					
equivalency of agents in	A vote was taken, and the results were				
class.	attendance (in favor, against, and abst	entions where	e appli	cable):	
			<b>N</b> 1 -	A least	
	Mark Dasarba Dharm D. Chair	Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair     Kata Ward, Pharm D., Vice Chair				
	<ul><li>Kate Ward, Pharm.D., Vice-Chair</li><li>Joseph Adashek, MD</li></ul>				
	<ul><li>Joseph Adashek, MD</li><li>Mark Crumby, Pharm.D</li></ul>				
	<ul><li>Mark Crumby, Pharm.D</li><li>Elizabeth Gonzalez, Pharm.D.</li></ul>			$\boxtimes$	
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>		$\Box$	$\triangle$	

		Sapandeep Khurana, MD	$\boxtimes$			
		<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
		Leana Ramirez, Pharm.D	$\boxtimes$			
		Aditi Singh, MD	$\boxtimes$			
		•				
	iv. Presentation of	Dr. Mishra recommending moving Nucy	nta to prefe	rred ar	nd also adding	
	recommendations for	Nucynta ER to class as preferred. Recom	mending re	movin	g Ultram from	
	PDL inclusion by	PDL due to manufacture discontinue.				
	MagellanRx					
	v. Discussion by Board and	Chairman Decerbo moved to approve th		_		
	action by Board for	presented by Magellan and Board Meml	ber Khurana	secon	aea tne	
	approval of drugs for inclusion on the PDL.	motion.				
	inclusion on the PDL.	A vote was taken, and the results were a	s follows fr	am mai	mhars in	
		attendance (in favor, against, and abster				
		atternative (iii lavor, against, and abster	TOTIS WITCH	с аррп	cabic).	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
		Joseph Adashek, MD			$\boxtimes$	
		Mark Crumby, Pharm.D	$\boxtimes$			
		Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
		Sapandeep Khurana, MD	$\boxtimes$			
		Isabella Niezborala, Pharm.D			$\boxtimes$	
		Leana Ramirez, Pharm.D	$\boxtimes$			
		Aditi Singh, MD	$\boxtimes$			
			<u>r 3</u>	_	_	
L	For Possible Action: Discussion					
	and possible adoption of					
	Leukotriene Receptor					
	Antagonists.					
	i. <u>Public Comment</u>	Telephonic and web comment was calle	d for, and the	ne phoi	ne lines were	

		opened.					
		No public comment was provided.					
ii.	Drug class review	Dr. Mishra recommended the Board cor	sider the cla	ass clin	ically and		
	presentation by	therapeutically equivalent.			•		
	MagellanRx						
iii.	Discussion by Board and	Chairman Decerbo moved to accept the class as clinically and					
	action by Board to	therapeutically equivalent presented by	Magellan a	nd Boa	rd Member		
	approve clinical/therapeutic	Ramirez seconded the motion.  A vote was taken, and the results were as follows from members in					
	equivalency of agents in						
	class.	attendance (in favor, against, and abster					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$				
		Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
		<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$		
		Mark Crumby, Pharm.D	$\boxtimes$				
		Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
		Sapandeep Khurana, MD	$\boxtimes$				
		<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$		
		<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$				
		Aditi Singh, MD	$\boxtimes$				
iv.	Presentation of	Dr. Mishra recommended moving Zyflo	from prefer	red to	non-preferred		
	recommendations for	and removing Zyflo CR from the PDL due	to manufa	cture d	iscontinue.		
	PDL inclusion by						
	MagellanRx						
V.	Discussion by Board and	Chairman Decerbo to approve the propo	sed change	s as pr	esented by		
	action by Board for approval of drugs for	Magellan and Vice-Chair Ward seconded					
	inclusion on the PDL.	A vote was taken, and the results were a	s follows fro	om me	mbers in		

	attendance (in favor, against, and absten				
		Yes	No	Abst.	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			
	Joseph Adashek, MD			$\boxtimes$	
	Mark Crumby, Pharm.D	$\boxtimes$			
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$	
	Sapandeep Khurana, MD	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	Leana Ramirez, Pharm.D	$\boxtimes$			
	Aditi Singh, MD	$\boxtimes$			
<ul><li>M. For Possible Action: Discussion and possible adoption of Vasodilators – Oral</li></ul>					
i. <u>Public Comment</u>	Telephonic and web comment was called opened.  No public comment was provided.	for, and th	ne pho	ne lines were	
<ul><li>ii. Drug class review presentation by MagellanRx</li></ul>	Dr. Mishra recommended the Board constitution therapeutically equivalent.	ider the cl	ass clin	ically and	
<ul><li>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</li></ul>	Chairman Decerbo moved to accept the of therapeutically equivalent presented by I Khurana seconded the motion.  A vote was taken, and the results were as attendance (in favor, against, and absten				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$			

	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	<ul> <li>Mark Crumby, Pharm.D</li> </ul>	$\boxtimes$			
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$	
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
	<ul> <li>Aditi Singh, MD</li> </ul>	$\boxtimes$			
	D. Miller and J. J. P. J. P. J.			III .	
<ul><li>iv. Presentation of recommendations for PDL</li></ul>	Dr. Mishra recommended adding Liqrev suspension as non-preferred and leaving	•		•	
inclusion by MagellanRx	preferred suspension.	Revalio sus	spensic	ni as tile	
melasion by Magenania	preferred suspension.				
v. Discussion by Board and	Vice-Chair Ward moved to approve the p	roposed ch	anges	as presented	
action by Board for	by Magellan and Chairman Decerbo seco				
approval of drugs for					
inclusion on the PDL.	A vote was taken, and the results were a				
	attendance (in favor, against, and abster	tions where	e applio	cable):	
		Yes	No	Abst.	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$			
	<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>	$\boxtimes$			
	<ul> <li>Joseph Adashek, MD</li> </ul>			$\boxtimes$	
	<ul> <li>Mark Crumby, Pharm.D</li> </ul>	$\boxtimes$			
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			$\boxtimes$	
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\boxtimes$			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			$\boxtimes$	
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>	$\boxtimes$			
	<ul> <li>Aditi Singh, MD</li> </ul>	$\boxtimes$			
<b>N.</b> For Possible Action: Discussion					
and possible adoption of Vasodilators – Inhaled					
vasouliators – Illilaieu					

i. <u>Public Comment</u>	Telephonic and web comment was calle opened.  No public comment was provided.	d for, and the phone lines were	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board con therapeutically equivalent.	sider the class clinically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairman Decerbo moved to accept the therapeutically equivalent presented by Ramirez seconded the motion.  A vote was taken, and the results were a attendance (in favor, against, and abster	Magellan and Board Member s follows from members in	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>	Yes No Abst.  □	
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Raj Mishra recommended moving Ty leaving the Tyvaso inhaler solution as pr	· · · · · · · · · · · · · · · · · · ·	
v. Discussion by Board and action by Board for	Chairman Decerbo moved to approve th presented by Magellan and Vice-Chair W	, ,	

approval of drugs for inclusion on the PDL.	<ul> <li>A vote was taken, and the results were as foll attendance (in favor, against, and abstention)</li> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>		
O. For Possible Action: Discussion and possible adoption of Monoclonal Antibodies for Respiratory Conditions.			
i. <u>Public Comment</u>	Telephonic and web comment was called for opened.  Public comment was provided by Ann Lyons, Scientific Affairs.		
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider therapeutically equivalent.	the class clinically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Chairman Decebro moved to accept the class therapeutically equivalent presented by Mag seconded the motion.		

equivalency of agents in class.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>	Yes	No	Abst.		
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommending moving Xolair keeping the Xolair syringe as preferred.	vial to non-	-prefer	red while		
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice-Chair Ward moved to approve the post of the post	s follows fro	the mo om mei e appli	ntion. mbers in cable):		
	Mark Decerbo, Pharm.D., Chair	Yes ⊠	No	Abst.  □		
	Kate Ward, Pharm.D., Vice-Chair	$\boxtimes$				
	Joseph Adashek, MD			$\boxtimes$		
	Mark Crumby, Pharm.D	$\boxtimes$				
	Elizabeth Gonzalez, Pharm.D.			$\boxtimes$		
	Sapandeep Khurana, MD	$\boxtimes$				

	Isabella Niezborala, Pharm.D
	• Leana Ramirez, Pharm.D
	◆ Aditi Singh, MD
P. Annual Review -	
Established Drug Classes	
without Proposed	
Changes	
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.
	Public comment was provided by Robin Reedy with National Alliance on Mental Illness.
	Public comment was provided by Phil Wettestad, Pharmacist and
	Medical Science Liaison with Novartis.
	Public comment was provided by Charlotte Wincott, Associate Director
	of Medical Affairs at Axon Therapeutics.
	Dublic comment was provided by lossics lay Dharmanist with Indivier
	Public comment was provided by Jessica Jay, Pharmacist with Indivior  Medical Outcomes and Value Liaison Team.
	Medical Odtcomes and value Liaison Team.
	Public comment was provided by Kenneth Berry, Pharmacist and
	Medical Science Director with Alchemies.
	Medical Science Director with Althemies.
iv. Discussion by Board	Board member Khurana block motion to approve the established drug
and action by Board for	classes without changes as presented by Magellan and Vice-Chair Ward
approval of drugs for	seconded the motion.
inclusion on the PDL.	
	A vote was taken, and the results were as follows from members in
	attendance (in favor, against, and abstentions where applicable):
	Yes No Abst.

	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> </ul>	$\boxtimes$		
	<ul> <li>Kate Ward, Pharm.D., Vice-Chair</li> </ul>	$\boxtimes$		
	<ul> <li>Joseph Adashek, MD</li> </ul>			
	<ul> <li>Mark Crumby, Pharm.D</li> </ul>			
	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> </ul>			
	<ul> <li>Sapandeep Khurana, MD</li> </ul>			
	<ul> <li>Isabella Niezborala, Pharm.D</li> </ul>			
	<ul> <li>Leana Ramirez, Pharm.D</li> </ul>			
	<ul> <li>Aditi Singh, MD</li> </ul>	$\boxtimes$		
<b>State of Nevada Medication Assistance</b>	Program (NMAP)			
<b>Q.</b> For Possible Action:				
Discussion and possible				
adoption of Substance Use				
Disorder Medications				
Class.	Talanda da anti-alanda anti-al	U. d.C d.d	L P	
i. <u>Public Comment</u>	Telephonic and web comment was ca opened.	liled for, and the p	none lines were	
	оренец.			
	Public comment was provided by Joh	n Phoenix, Family I	Nurse	
	Practitioner with the Huntridge Famil			
	Ç	,		
	Public comment was provided by Joh	n Landis on behalf	of Brixadi.	
	Public comment was provided by Jess	•	st with Indivior	
	Medical Outcomes and Value Liaison	Team.		
			56 1	
ii. Drug class review	Dr. Mishra presented the addition of	•	•	
presentation by	recommendation for generic naltrexo		•	
MagellanRx	(sublingual), buprenorphine/naloxono spray (nasal) included in coverage.	e tan (Subiiligual), i	and naioxone	
	spray (nasar) included in coverage.			

iii. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairman Decerbo moved to approve to use disorder medications as well as within NMAP that these four agents be the initiounder the founding of this new class. Vice motion.  A vote was taken, and the results were as attendance (in favor, against, and abstern				
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>	Yes	No	Abst.  □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
iv. Board Member Comments	Comment provided from Board Member for the NMAP program to consider some discussed and then we can revisit them in Comment provided from Board Member being part of the 340B program, that is dishould consider.	of the disc n subseque Ramirez th	ussion nt mee at with	s that we were etings.	
R. Annual Review NMAP- Established Drug Classes without Proposed Changes					
i. Public comment	Telephonic and web comment was called opened.	for, and th	ne pho	ne lines were	

ii. Discussion by Board and action by Board for approval of the annual review drug classes without proposed changes as presented by Magellan and Vice-Chair Ward seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  Yes No Abst.  Mark Decerbo, Pharm.D., Chair  Kate Ward, Pharm.D., Vice-Chair  Joseph Adashek, MD
<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice-Chair</li> <li>Joseph Adashek, MD</li> </ul>
<ul> <li>Mark Crumby, Pharm.D</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D</li> <li>Leana Ramirez, Pharm.D</li> <li>Aditi Singh, MD</li> </ul>
Reports
S. MagellanRx Reports  MRx Pipeline  OPHTHALMOLOGY  HEMATOLOGY/GENE THERAPY  MUSCULOSKELETAL  IMMUNOLOGY  EDOCRINOLOGY  BLOOD MODIFIER
T. Closing Discussion
i. Public comments on any No public comments were provided. subject
ii. Date and location of the next meeting.  Date: December 14, 2023.  Location: TBD  Note: Possible emergency board meeting next week (TBD)
iii. Adjournment Chairman Decerbo adjourned the meeting at 4:28 PM.

## Attachment A – Members of the Public in Attendance

Eileen	Zimmer	Kenneth	Berry	Georgette	Dzwilewski	Paul	Miner
Deron	Grothe	Kheelan	Gopal	Jessica	Jay	Lisa	Ashton
Phil	Wettestad	Mandeep	Sohal	Dan	O'Donnell	Bryan	Dillon
Michael	Zarob	Chris J	Gilbert	Mark	Rosenberg	Luke	Lim
Deborah	Guay	Joe	Gelinas	Dustin	Washburn	Ryan	Roa
Peter	Barrio	Lea	Case	John	Landis	Luke	Lim
Rodney	Cobb	Michael	Pazirandeh	Alex	Tanchek	Jason	Douglas
Ann	Lyons	Nick	Boyer	Misty	Harvey	Elyse	Monroy-Marsala
Robin V	Reedy	Areli	Alarcon	Carin	Fox Hennessey	Joseph	Germain Jr.
Charlotte	Wincott	Amy	Delacluyse	Amy	Breen	Michele	Puyear
John	Phoenix	Shannon	Groppenbacher	Melissa	Roy	James	D

## **Attachment B – Submitted Written Comment**

Bovrick Integrated Health - Rexulti

<u>Axsome Therapeutics</u> <u>Solidarity Mental Health Services</u>

Frontier Medical & Behavioral Center

Pharmacy & Therapeutics Committee